Your browser doesn't support javascript.
loading
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard, Paul; Gervais, Adrian; Taniguchi, Maki; Saare, Liisa; Särekannu, Karita; Le Voyer, Tom; Philippot, Quentin; Rosain, Jérémie; Bizien, Lucy; Asano, Takaki; Garcia-Prat, Marina; Parra-Martínez, Alba; Migaud, Mélanie; Tsumura, Miyuki; Conti, Francesca; Belot, Alexandre; Rivière, Jacques G; Morio, Tomohiro; Tanaka, Junko; Javouhey, Etienne; Haerynck, Filomeen; Duvlis, Sotirija; Ozcelik, Tayfun; Keles, Sevgi; Tandjaoui-Lambiotte, Yacine; Escoda, Simon; Husain, Maya; Pan-Hammarström, Qiang; Hammarström, Lennart; Ahlijah, Gloria; Abi Haidar, Anthony; Soudee, Camille; Arseguel, Vincent; Abolhassani, Hassan; Sahanic, Sabina; Tancevski, Ivan; Nukui, Yoko; Hayakawa, Seiichi; Chrousos, George P; Michos, Athanasios; Tatsi, Elizabeth-Barbara; Filippatos, Filippos; Rodriguez-Palmero, Agusti; Troya, Jesus; Tipu, Imran; Meyts, Isabelle; Roussel, Lucie; Ostrowski, Sisse Rye; Schidlowski, Laire; Prando, Carolina.
Afiliação
  • Bastard P; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Gervais A; University Paris Cité, Imagine Institute , Paris, France.
  • Taniguchi M; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University , New York, NY, USA.
  • Saare L; Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris (AP-HP) , Paris, France.
  • Särekannu K; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Le Voyer T; University Paris Cité, Imagine Institute , Paris, France.
  • Philippot Q; Dept. of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Rosain J; Dept. of Pediatrics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
  • Bizien L; Molecular Pathology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Asano T; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Garcia-Prat M; University Paris Cité, Imagine Institute , Paris, France.
  • Parra-Martínez A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Migaud M; University Paris Cité, Imagine Institute , Paris, France.
  • Tsumura M; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Conti F; University Paris Cité, Imagine Institute , Paris, France.
  • Belot A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Rivière JG; University Paris Cité, Imagine Institute , Paris, France.
  • Morio T; Dept. of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Tanaka J; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB) , Barcelona, Spain.
  • Javouhey E; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB) , Barcelona, Spain.
  • Haerynck F; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Duvlis S; University Paris Cité, Imagine Institute , Paris, France.
  • Ozcelik T; Dept. of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Keles S; Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna, Italy.
  • Tandjaoui-Lambiotte Y; Dept. of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Escoda S; National Reference Center for Rheumatic, and Autoimmune and Systemic Diseases in Children , Lyon, France.
  • Husain M; Immunopathology Federation LIFE, Hospices Civils de Lyon , Lyon, France.
  • Pan-Hammarström Q; Hospices Civils de Lyon , Lyon, France.
  • Hammarström L; International Center of Research in Infectiology, Lyon University, International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL , Lyon, France.
  • Ahlijah G; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB) , Barcelona, Spain.
  • Abi Haidar A; Dept. of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Soudee C; Dept. of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Arseguel V; Pediatric Intensive Care Unit, Hospices Civils de Lyon, Hopital Femme Mère Enfant , Lyon, France.
  • Abolhassani H; Dept. of Paediatric Immunology and Pulmonology, Center for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Center, Ghent University Hospital, Ghent, Belgium.
  • Sahanic S; Faculty of Medical Sciences, University "Goce Delchev" , Stip, Republic of Northern Macedonia.
  • Tancevski I; Institute of Public Health of the Republic of North Macedonia , Skopje, North Macedonia.
  • Nukui Y; Dept. of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.
  • Hayakawa S; Meram Medical Faculty, Necmettin Erbakan University , Konya, Turkey.
  • Chrousos GP; Pulmonology and Infectious Disease Department, Saint Denis Hospital, Saint Denis, France.
  • Michos A; INSERM UMR 1137 IAME, Paris, France.
  • Tatsi EB; INSERM UMR 1272 Hypoxia and Lung, Bobigny, France.
  • Filippatos F; Pediatric Dept., Saint-Denis Hospital, Saint-Denis, France.
  • Rodriguez-Palmero A; Pediatric Dept., Saint-Denis Hospital, Saint-Denis, France.
  • Troya J; Division of Immunology, Dept. of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Tipu I; Division of Immunology, Dept. of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Meyts I; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Roussel L; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Ostrowski SR; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Schidlowski L; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
  • Prando C; Division of Immunology, Dept. of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
J Exp Med ; 221(2)2024 Feb 05.
Article em En | MEDLINE | ID: mdl-38175961
ABSTRACT
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-ß in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-ω and/or IFN-α2.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferon Tipo I / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferon Tipo I / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article